Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $15.60 Consensus PT from Brokerages

Key Points

• Kyverna Therapeutics, Inc. has received a consensus rating of "Buy" from analysts, with an average target price set at $15.60.
• The company's shares opened at $3.70, showing a market capitalization of approximately $160.01 million, with notable price fluctuations between $1.78 and $8.28 over the past year.
• Kyverna's lead product candidate, KYV-101, is currently in clinical trials for several autoimmune diseases, indicating an active development pipeline.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has earned an average rating of "Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $16.60.

KYTX has been the topic of a number of research reports. HC Wainwright boosted their target price on shares of Kyverna Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday. William Blair assumed coverage on shares of Kyverna Therapeutics in a research report on Wednesday, August 20th. They set an "outperform" rating on the stock.

Institutional Trading of Kyverna Therapeutics

Institutional investors have recently bought and sold shares of the company. Phoenix Wealth Advisors bought a new stake in Kyverna Therapeutics during the second quarter valued at $32,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Kyverna Therapeutics during the second quarter valued at about $37,000. Squarepoint Ops LLC acquired a new position in shares of Kyverna Therapeutics during the fourth quarter valued at about $43,000. Qube Research & Technologies Ltd acquired a new position in shares of Kyverna Therapeutics during the second quarter valued at about $43,000. Finally, Corton Capital Inc. acquired a new position in shares of Kyverna Therapeutics during the fourth quarter valued at about $45,000. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX traded up $0.02 during midday trading on Friday, reaching $3.61. The company's stock had a trading volume of 15,955 shares, compared to its average volume of 363,729. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $7.85. The business's 50 day moving average price is $3.55 and its two-hundred day moving average price is $2.84. The company has a market cap of $155.92 million, a P/E ratio of -0.98 and a beta of 3.08.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.03. Sell-side analysts forecast that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.